| Chirfi Guindo |
Chirfi Guindo is currently the Chief Marketing Officer-Human Health & SVP at Merck & Co., Inc. He previously served as the President & Managing Director at Merck Canada, Inc. from 2014 to 2017 and as the EVP-Global Product Strategy & Commercialization at Biogen, Inc. from 2018 to 2022. Mr. Guindo completed his undergraduate degree at École Centrale Paris and holds an MBA from The Leonard N Stern School of Business. |
| Caroline A. Litchfield |
Caroline A. Litchfield is currently the Chief Financial Officer & Director at Immune Design Corp. and the Chief Financial Officer & Executive Vice President at Merck & Co., Inc. She previously worked as a Director at Fulford (India) Ltd., Finance Director at Organon Pharma (UK) Ltd., and Director at Organon & Co. Ms. Litchfield obtained her undergraduate degree from the University of Leicester. |
| Robert M. Davis |
Robert M. Davis is currently the Chairman, President & Chief Executive Officer at Merck & Co., Inc. He is also the President, Chief Executive Officer & Director at MSD Pharma (Singapore) Pte Ltd. Additionally, he holds the position of Chairman at Gambro AB and serves as a Director at Catalyst, Inc., Duke Energy Corp., Project HOPE-The-People-To-People Health Foundation, Inc., and AdvaMedDx. In his former positions, Mr. Davis served as a Director at C. R. Bard, Inc. (New Jersey) from 2015 to 2017. He was the Director-Corporate Financial Planning at Eli Lilly & Co. from 1990 to 2004. From 2004 to 2010, he held the role of Chief Financial Officer & Vice President at Baxter Healthcare Corp. He then became the VP & President-Medical Products Business at Baxter International, Inc. from 2010 to 2014. He also served as a Trustee at Rush University Medical Center. Mr. Davis completed his undergraduate degree at Miami University. He obtained an MBA from Kellogg School of Management. He also holds a graduate degree from Northwestern University School of Law. |
| Betty D. Larson |
Ms. Betty D. Larson is a Chief Human Resources Officer & Executive VP at Merck & Co., Inc. and a President & Secretary at BD Foundation, Inc. She is on the Board of Directors at Baxter Credit Union. Ms. Larson was previously employed as an Independent Director by Fortrea Holdings, Inc., a Chief People Officer by GE Healthcare Technologies, Inc., a Chief Human Resources Officer & Executive VP by Becton, Dickinson & Co., a Vice President-Human Resources by C. R. Bard, Inc. (New Jersey), and a Senior Vice President-Human Resources by Baxter Healthcare Corp. She also served on the board at Overlook Foundation (United States), Summit Speech School and United Way of Lake County. She received her undergraduate degree from the University of Illinois, a graduate degree from the University of Illinois and an MBA from Northwestern University. |
| Michael Klobuchar |
Michael Klobuchar is currently an Independent Director at Revvity, Inc. and the Chief Strategy Officer & Executive Vice President at Merck & Co., Inc. He previously worked as the CFO, SVP & Head-Portfolio and Alliance Management at Merck Research Laboratories Massachusetts LLC and as the President at Merck Global Health Innovation Fund LLC. Mr. Klobuchar holds a graduate degree from Rutgers State University of New Jersey, an undergraduate degree from Purdue University, and an MBA from Villanova University. |
| Dave Williams |
Dave Williams is the founder of Merck Animal Health Ventures. He currently holds the position of Chief Information & Digital Officer at Merck & Co., Inc. and Director at National Center for Women & Information Technology. Previously, he worked as Chief Information Officer at Merck Animal Health. He completed his undergraduate degree at the University of Scranton. |
| Jannie Oosthuizen |
Jannie Oosthuizen currently works at Merck & Co., Inc., as President-Merck Human Health from 2021, Merck Human Health US, as President from 2022, and Esor Ltd., as Manager-Legal & Human Resources. Mr. Oosthuizen received his graduate degree from North-West University. |
| Allan Gabor |
Allan Gabor has worked as the President-Asian-Pacific-BioPharma Business at Merck & Co., Inc. since 2013. |
| Joseph Romanelli |
Joseph Romanelli is currently the President-Human Health International at Merck & Co., Inc. Prior to this, he was the Chief Executive Officer at Jixing Pharmaceutical Technology (Shanghai) Co. Ltd. from 2021 to 2022. He worked at Merck & Co., Inc. from 1996 to 2015 as the Head-Investor Relations. He also held the same position at Schering-Plough Corp. Mr. Romanelli received his undergraduate degree from the University of Delaware and his MBA from Gabelli School of Business. |
| Inge G. Thulin |
Inge G. Thulin is currently serving as the Vice Chairman at the United States Council for International Business and the Vice Chairman at The Kennedy Center Corporate Fund. He is also an Independent Director at Merck & Co., Inc., a Director at The Council for the United States & Italy, a Director at Merck Sharp & Dohme Corp., a Director at Patricia Industries AB, a Director at MSD Pharma (Singapore) Pte Ltd., and a Member of the Council on Foreign Relations, Inc., The Business Roundtable, The Business Council, The World Economic Forum USA, Inc., The International Business Council, and Sällskapet. In his former positions, Mr. Thulin served as the Executive Chairman at 3M Co., an Independent Director at Chevron Corp., an Independent Director at The Toro Co., the Managing Director at 3M Russia ZAO, and held managerial roles at 3M Svenska AB and 3M Europe NV. He was also a Member of Forum Mondial de L'Economie. Mr. Thulin completed his undergraduate degree at the University of Gothenburg. |
| Mary Ellen Coe |
Mary Ellen Coe is currently an Independent Director at Merck & Co., Inc., a Director at Merck Sharp & Dohme Corp., a Director at MSD Pharma (Singapore) Pte Ltd., and the President-Global Customer Solutions at Google LLC. She previously served as an Independent Director at Whole Foods Market, Inc. from 2016 to 2017. Ms. Coe completed her undergraduate degree at the University of Michigan. |
| Christine E. Seidman |
Christine E. Seidman is the founder of MyoKardia, Inc. She is currently an Independent Director at Merck & Co., Inc. and the Director of Cardiovascular Genetics Center at The Brigham & Women's Hospital, Inc. She is also a Director at Merck Sharp & Dohme Corp., MSD Pharma (Singapore) Pte Ltd., and The Burroughs Wellcome Fund. Additionally, she is a Member of the National Academy of Sciences, American Academy of Arts & Sciences, National Academy of Medicine (United States), and American Society for Clinical Investigation. She is a Professor at Harvard Medical School and a Member of the Association of University Cardiologists. She serves on the Scientific Advisory Board of BridgeBio Pharma, Inc. and is a Venture Partner at Catalio Capital Management LP. She received her undergraduate degree from Harvard University and her doctorate from George Washington University. |
| Pamela J. Craig |
Pamela J. Craig is currently serving as Vice Chairman at The Committee of 200, Independent Director at Corning, Inc., Merck & Co., Inc., and Progressive Corp. She is also a Director at Smith College, Junior Achievement of New Jersey, Inc., Merck Sharp & Dohme Corp., Comprehensive Development, Inc., and MSD Pharma (Singapore) Pte Ltd. Previously, she served as Chairman at C200 Foundation, Independent Director at 3M Co., Walmart, Inc., Akamai Technologies, Inc., and VMware, Inc. She was also the Chief Financial Officer at Accenture Ltd., Accenture SCA, Accenture Plc, Accenture LLP, and Avanade, Inc. Ms. Craig completed her undergraduate degree at Smith College and earned an MBA from The Leonard N Stern School of Business. |
| Patricia Fiorello Russo |
Patricia Fiorello Russo is currently an Independent Chairman at Hewlett Packard Enterprise Co. and an Independent Director at Merck & Co., Inc., KKR Management LLC, General Motors Co., KKR Group Co., Inc., Merck Sharp & Dohme Corp., Arconic Defense, Inc., MSD Pharma (Singapore) Pte Ltd., KKR & Co., Inc., The Conference Board, Inc., The Economic Club of New York, and The Business Council. She previously held positions as Chairman & Chief Executive Officer at Lucent Technologies, Inc., Chief Executive Officer & Director at Nokia of America Corp., Chief Executive Officer at Alcatel Lucent SA, Chairman at Avaya, Inc., Chairman at Partnership for Drug-Free Kids, Lead Independent Director at Arconic, Inc., Lead Independent Director at HP, Inc., and Director at Schering-Plough Corp. She also served as a Director at Motors Liquidation Co., Alcoa Corp., DXC Technology Co., and Howmet Aerospace, Inc. Additionally, she was President & Chief Operating Officer at Eastman Kodak Co. and a Trustee at Georgetown University. Ms. Russo obtained her undergraduate degree from Georgetown University. |
| Peter C. Wendell |
Peter Wendell founded Sierra Ventures after ten years in sales and marketing at IBM, growing the firm from a single California-based partner to over a dozen investing professionals, nine funds, and $1.5 billion in committed capital. Peter co-teaches Stanford University’s Graduate School of Business, “Entrepreneurship and Venture Capital†with Google CEO, Eric Schmidt. Peter holds a BA from Princeton University and an MBA from Harvard. In addition to his venture capital activities at Sierra Ventures, Peter serves on the board of directors of Merck & Co., Inc. (NYSE:MRK), as one of the three officers of Princeton University’s 40-member board of trustees, and recently completed an extended term as a member of the board of the Princeton University Investment Company (PRINCO), including six years as chairman during which time PRINCO’s professional managers doubled the University’s endowment. In recognition of his work at Stanford and Princeton, Peter was awarded the National Venture Capital Association’s American Spirit Award. |
| Risa J. Lavizzo-Mourey |
Risa J. Lavizzo-Mourey is currently serving as an Independent Director at Intel Corp., Merck & Co., Inc., Princeton Medical Center, Merck Sharp & Dohme Corp., GE Healthcare, Inc., MSD Pharma (Singapore) Pte Ltd., Better Therapeutics LLC, GE Healthcare Technologies, Inc., and Healthquest Capital Management Co LLC. She is also a Trustee at the Howard Hughes Medical Institute, Inc. and a Member of the Regents Board at the Smithsonian Institution. Additionally, she is a Member of the National Academy of Sciences, the American Academy of Arts & Sciences, the National Academy of Medicine (United States), and the American Philosophical Society. Dr. Lavizzo-Mourey's former positions include President Emerita & CEO at The Robert Wood Johnson Foundation, Co-Chairman at White House Health Care & Rehabilitation Center, Inc., Independent Director at Hess Corp. and GE Aerospace, Director at Hanger, Inc., Beckman Coulter, Inc., Genworth Financial, Inc., and Independent Sector, and Deputy Administrator at the Agency for Healthcare Research & Quality. She was also a Professor at the University of Pennsylvania and held various roles at the Perelman School of Medicine and the Institute on Aging. Dr. Lavizzo-Mourey received her undergraduate degree from Stony Brook University, a doctorate from Harvard Medical School, and an MBA from The Wharton School of the University of Pennsylvania. |
| Douglas M. Baker |
Douglas M. Baker is currently the Chairman of ChampionX Holding, Inc. He is also an Independent Director at Merck & Co., Inc. and Target Corp. Additionally, he serves as a Director at the Minnesota Orchestral Association, Minneapolis Saint Paul Regional Economic Development Partners, Parent Aware For School Readiness, and College of the Holy Cross (Massachusetts), where he is a Trustee. Furthermore, he is a Trustee at Mayo Clinic and a Member of Chief Executives For Corporate Purpose, Inc. Mr. Baker is also a Trustee-Emeritus at the National Restaurant Association Educational Foundation. In addition to his current positions, he is a Founding Partner at E2SG Partners LP. Previously, Mr. Baker served as the Executive Chairman at Ecolab, Inc. from 1989 to 2022. He was also an Independent Director at U.S. Bancorp from 2008 to 2018. Additionally, he held a position as a Director at Nalco Holding Co.Mr. Baker obtained his undergraduate degree from the College of the Holy Cross (Massachusetts). |
| Paul B. Rothman |
Paul B. Rothman is an Independent Director at Laboratory Corp. of America Holdings and Merck & Co., Inc. He is also a Director at Merck Sharp & Dohme Corp., King Faisal Specialist Hospital & Research Centre, MSD Pharma (Singapore) Pte Ltd., and Center for Medical Interoperability. He is a Member of the American Academy of Arts & Sciences, American Association for the Advancement of Science, National Academy of Medicine (United States), Association of American Physicians, and American Society for Clinical Investigation. He is an Ex-Officio Trustee at The Johns Hopkins Hospital, Inc. and a Trustee at Johns Hopkins Community Physicians, Inc. His former positions include Chief Executive Officer at Johns Hopkins Medicine, Inc., Dean at the University of Iowa Carver College of Medicine, and Director at Cancer Genetics, Inc. He holds an undergraduate degree from Massachusetts Institute of Technology and a doctorate from Yale University. |
| Stephen L. Mayo |
Stephen L. Mayo is the founder of Xencor, Inc. founded in 1997. He is currently an Independent Director at Merck & Co., Inc., Sarepta Therapeutics, Inc., MSD Pharma (Singapore) Pte Ltd., and an Independent Director at Allogene Therapeutics, Inc. He is also a Professor at California Institute of Technology since 2007. Dr. Mayo was a Director at American Association for the Advancement of Science from 2010 to 2014 and a Director at The National Science Foundation from 2013 to 2018. He received his doctorate degree from California Institute of Technology in 1987 and his undergraduate degree from The Pennsylvania State University in 1983. Dr. Mayo is also the founder of BIOVIA, Inc., Molecular Simulations, Inc., Protabit LLC. |
| Kathy J. Warden |
Kathy J. Warden is currently the Chairman, President & Chief Executive Officer at Northrop Grumman Corp. She is also the Chairman at the Federal Reserve Bank of Richmond and the Vice Chairman at the Greater Washington Partnership. Additionally, she serves as an Independent Director at Merck & Co., Inc., a Director at Catalyst, Inc., and a Director at Merck Sharp & Dohme Corp. She is also a Director at Wolf Trap Foundation for the Performing Arts and MSD Pharma (Singapore) Pte Ltd. Furthermore, she is a Member-Visitors Board at James Madison University and a Member of The Business Roundtable and AFCEA International. Formerly, Ms. Warden served as the Vice Chairman at Aerospace Industries Association, the Director-Global Services Operating Unit at General Electric Information Services, and the Senior Manager at GE Aerospace. She was also the Senior Vice President at Veridian Corp. and the President of Northrop Grumman Information Technology, Inc. She held the position of Vice President & GM-Cyber Intelligence Division at Northrop Grumman Information Technology, Inc. and served as the President of Northrop Grumman Mission Systems. Additionally, she was the Vice President-Intelligence Systems at General Dynamics Advanced Information Systems, Inc.Ms. Warden holds an MBA from George Washington University and an undergraduate degree from James Madison University. |
| Thomas Henry Glocer |
Thomas Henry Glocer founded Angelic Ventures LP in 2012, where he is working as Founding Partner from 2012, Capitolis, Inc. in 2017, where he is working as Executive Chairman from 2017, Communitas Capital Partners LLC in 2017, where he is working as Partner from 2017, and various other companies. Mr. Glocer also currently works at Blueteam Investor LLC, as Chief Executive Officer, Merck & Co., Inc., as Lead Independent Director from 2021, Morgan Stanley, as Lead Independent Director from 2017, and various other companies. Mr. Glocer also formerly worked at Reuters Group Plc, as Chief Executive Officer & Director from 2001 to 2008, Thomson Reuters Plc, as Chief Executive Officer from 2001 to 2009, Thomson Reuters Corp., as Chief Executive Officer & Director from 2008 to 2011, and various other companies. Mr. Glocer received his undergraduate degree in 1981 from The Trustees of Columbia University in The City of New York and graduate degree in 1984 from Yale University. |
